Synlogic reports positive PKU data: SYNB1618 reduces Phe, SYNB1934 shows 2x activity

SYNLOGIC, INC.

SYNB1618 showed 20% reduction in fasting plasma Phe after 14 days at 1e12 dose in Phase 2 SynPheny-1 interim analysis.
SYNB1934 demonstrated two-fold higher activity than SYNB1618 in head-to-head Phase 1 study based on biomarkers of Phe metabolism.
Safety profile consistent with prior studies: no serious AEs, no drug-related discontinuations; AEs mild-moderate GI.
Company plans to complete Phase 2 SynPheny-1 with SYNB1934 arm and prepare Phase 3 program for most promising strain in 2022.
Shares trade on Nasdaq under SYBX; data support Synthetic Biotic platform for metabolic diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.